Business Context and Reporting Period
This Form 8-K, filed on December 20, 2017, reports that Artelo Biosciences, Inc. (formerly Knight Knox Development Corp. and Reactive Medical, Inc.) has ceased to be a "shell company" following the execution of a Material and Data Transfer, Option and License Agreement (the "NEOMED Agreement") with NEOMED Institute. The Company is an early-stage biopharmaceutical firm focused on licensing, developing, and commercializing treatments that modulate the endocannabinoid system (ECS). The financial data provided in the filing reflects the period ended August 31, 2017.
Key Financial Metrics
The filing incorporates financial statements for the fiscal year ended August 31, 2017. The Company has generated no revenue since inception.
| Metric | Year Ended Aug 31, 2017 | Year Ended Aug 31, 2016 |
|---|---|---|
| Operating Revenue | $0 | $0 |
| Total Expenses | $234,889 | $29,690 |
| Net Loss | $(234,889) | $(29,690) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.00) |
| Cash and Cash Equivalents | $572,775 | $3,590 |
| Working Capital | $544,837 | $(13,800) |
| Accumulated Deficit | $(295,089) | N/A |
Capital Structure: As of December 21, 2017, there were 11,352,302 shares of common stock outstanding. The Company also has 1,952,302 Series A Warrants outstanding exercisable at $1.00 per share.
Material Changes
- Change in Shell Status: The Company transitioned from a shell company to an operating entity upon closing the NEOMED Agreement on December 20, 2017.
- Strategic Acquisition: The Company secured rights to conduct non-clinical research on NEO1940 (formerly AZD1940), a proprietary therapeutic compound from NEOMED, and obtained an option for an exclusive worldwide license to develop and commercialize products containing the compound.
- Liquidity Improvement: Cash on hand increased significantly from $3,590 in 2016 to $572,775 in 2017, primarily driven by a private placement offering in July 2017 that raised approximately $780,921.
- Expense Growth: Operating expenses increased to $232,789 in 2017 from $29,690 in 2016, reflecting costs associated with the new business plan, professional fees, and general administration.
Outlook, Risks, and Management Commentary
Outlook and Strategy: Management intends to pursue three scientific platforms: phytocannabinoids, synthetics/mimetics, and new chemical entities. The Company plans to conduct cancer-related research with the NEO1940 compound. However, management explicitly states that current financial resources are insufficient to fund business development over the next 12 months without additional financing.
Risks and Contingencies:
- Capital Requirements: The Company must raise significant additional capital to pursue its objectives. Failure to do so could result in the cessation of operations or the relinquishment of licensed rights.
- Regulatory Hurdles: Products may contain controlled substances (cannabis derivatives), subjecting the Company to strict DEA regulations, licensing requirements, and potential scheduling delays.
- Licensing Obligations: The Company holds licenses with Analog Biosciences and NEOMED. Failure to meet diligence provisions or raise capital to satisfy payment obligations could lead to termination of these agreements.
- Market Liquidity: Common stock trades on the OTC Pink Current Information tier under symbol "ARTL" with no established public trading market. Shares are subject to Rule 144 restrictions due to the Company's former shell status.
Investor Verification Checklist
- Verify the Company's ability to raise the necessary capital to fund operations for the next 12 months, as current cash reserves are deemed insufficient.
- Confirm the status of the NEOMED Agreement, specifically the timeline for receiving materials and the conditions for exercising the exclusive license option (including the $1.5 million fee and 2% equity grant).
- Review the terms of the Analog Biosciences license to ensure the Company can meet diligence requirements to avoid termination.
- Assess the regulatory pathway for NEO1940 and the Company's progress in obtaining necessary DEA licenses for research involving controlled substances.
- Monitor the Company's compliance with SEC reporting requirements to maintain its non-shell status and enable Rule 144 trading for shareholders.